Characterising the safety profile of lurasidone in clinical practice: A drug utilisation and safety study using a United Kingdom primary care database

07/04/2017
03/06/2026
EU PAS number:
EUPAS18536
Study
Planned
Subscribe
Download as PDF
Study summary
No information provided.
Study identification

EU PAS number

EUPAS18536

Study ID

18537

Official title and acronym

Characterising the safety profile of lurasidone in clinical practice: A drug utilisation and safety study using a United Kingdom primary care database

DARWIN EU® study

No

Study countries

United Kingdom

Study description

The study aims to describe drug utilisation patterns and characterise the safety profile of lurasidone compared with other second-generation antipsychotics in a real-world UK primary care setting

Study status

Planned
Research institutions and networks

Institutions

OXON Epidemiology
Spain
United Kingdom
First published:
03/06/2026
Institution Laboratory/Research/Testing facility Non-Pharmaceutical company ENCePP partner

Contact details

Nawab Qizilbash MBChB MRCP(UK) BSc MSc DPhil(Oxon.)

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Sunovion Pharmaceuticals Europe Ltd
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)